Arabic Arabic English English French French German German

AB Science announces the validation of its Risk Management Plan by the French National Agency (ANSM) in order to restart patient enrollment in France

AB Science SA announced that it has been informed by the French National Agency that the measures proposed by AB Science to reinforce patient safety in masitinib trials are acceptable to allow resumption of enrollment in its three ongoing studies; namely, the phase 3 study in mastocytosis, the phase 3 study in amyotrophic lateral sclerosis, and the phase 2 study in COVID-19. Read More

Leave a Reply

Your email address will not be published. Required fields are marked *

Previous Post

‘Wasfaty’ Service Activated in King Saud Medical City

Next Post

Sciwind Biosciences Appoints Dr. Weidong Zhong as Chief Strategy Officer and President of its US Subsidiary

Related Posts